ESR1 and breast carcinoma: Among 1522 patients with primary breast cancer ER+/PgR−/HER2- tumors showed poorer clinicopathologic characteristics compared with ER+/PgR+/HER2- tumors using a PgR threshold of 20% instead of 1% [27].